Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves' orbitopathy (MINGO): a randomised, observer-masked, multicentre trial

Autor: George J Kahaly, Michaela Riedl, Jochem König, Susanne Pitz, Katharina Ponto, Tanja Diana, Elena Kampmann, Elisa Kolbe, Anja Eckstein, Lars C Moeller, Dagmar Führer, Mario Salvi, Nicola Curro, Irene Campi, Danila Covelli, Marenza Leo, Michele Marinò, Francesca Menconi, Claudio Marcocci, Luigi Bartalena, Petros Perros, Wilmar M Wiersinga, Göksun Ayvaz, Lelio Baldeschi, Kostas Boborides, Antonella Boschi, Thomas H Brix, Lucy Clarke, Colin Dayan, Chantal Daumerie, A Jane Dickinson, Nicole Fichter, Laszlo Hegedüs, Onur Konuk, Gerassimos E Krassas, Carol Lane, John Lazarus, Dan S Morris, Maarten. Mourits, Marco Nardi, Chris Neoh, Jacques Orgiazzi, Simon H S Pearce, Georg von Arx, Milos Zarkovic

Publikováno v: Kahaly, G J, Riedl, M, König, J, Pitz, S, Ponto, K, Diana, T, Kampmann, E, Kolbe, E, Eckstein, A, Moeller, L C, Führer, D, Salvi, M, Curro, N, Campi, I, Covelli, D, Leo, M, Marinò, M, Menconi, F, Marcocci, C, Bartalena, L, Perros, P, Wiersinga, W M, European Group on Graves' Orbitopathy (EUGOGO), Hegedüs, L & Brix, T 2018, ' Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves' orbitopathy (MINGO) : a randomised, observer-masked, multicentre trial ', The Lancet Diabetes & Endocrinology, vol. 6, no. 4, pp. 287-298 . https://doi.org/10.1016/S2213-8587(18)30020-2
Lancet. Diabetes and endocrinology, 6(4), 287-298. Elsevier BV

BACKGROUND: European guidelines recommend intravenous methylprednisolone as first-line treatment for active and severe Graves' orbitopathy; however, it is common for patients to have no response or have relapse after discontinuation of treatment. We

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::edc4643f6e3fc6e4807c854403320050
https://pubmed.ncbi.nlm.nih.gov/29396246